0000950170-24-011271.txt : 20240205
0000950170-24-011271.hdr.sgml : 20240205
20240205162956
ACCESSION NUMBER: 0000950170-24-011271
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240201
FILED AS OF DATE: 20240205
DATE AS OF CHANGE: 20240205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schaefer Thomas J.
CENTRAL INDEX KEY: 0001960808
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37383
FILM NUMBER: 24596122
MAIL ADDRESS:
STREET 1: 202 COUSTEAU PLACE STE 105
CITY: DAVIS
STATE: CA
ZIP: 95618
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Arcadia Biosciences, Inc.
CENTRAL INDEX KEY: 0001469443
STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE PRODUCTION - CROPS [0100]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 810571538
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 202 COUSTEAU PLACE
STREET 2: SUITE 105
CITY: DAVIS
STATE: X1
ZIP: 95618
BUSINESS PHONE: 530-756-7077
MAIL ADDRESS:
STREET 1: 202 COUSTEAU PLACE
STREET 2: SUITE 105
CITY: DAVIS
STATE: CA
ZIP: 95618
4
1
ownership.xml
4
X0508
4
2024-02-01
0001469443
Arcadia Biosciences, Inc.
RKDA
0001960808
Schaefer Thomas J.
C/O ARCADIA BIOSCIENCES, INC.
5950 SHERRY LANE, SUITE 215
DALLAS
TX
75225
false
true
false
false
Chief Financial Officer
false
Common Stock
2024-02-01
4
P
false
700
2.06
A
1419
D
Reflects the purchase of 700 shares of the Issuer's common stock on 2/1/24 at a per share purchase price of $2.06 pursuant to participation in the Issuer's 2015 Employee Stock Purchase Plan ("ESPP"). This transaction is exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of Issuer's common stock.
The amount includes the 2015 Employee Stock Purchase Plan ("ESPP") purchases, for the purchase periods from February 1, 2021 to February 1, 2024. These transactions were exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of Issuer's Common Stock on the date of each respective purchase.
Thomas J. Schaefer, by Attorney-in-fact, Solaeta Chan
2024-02-05